In:
Annals of the Rheumatic Diseases, BMJ, Vol. 81, No. Suppl 1 ( 2022-06), p. 1738.1-1738
Abstract:
Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It’s classified into subtypes with different relative prevalences depending on geographical area (Oligarticular subtype predominates in Western Europe/North America. Enthesitis-related arthritis subtype predominates in Eastern Europe/Asia). To ensure continuity of care in adult rheumatology services, a systematic transition process is recommended. Various authors recommend that the process, of which pediatric and adult rheumatology teams should be part, begins around 14 years and ends around 18 years of age. Objectives We aim to study the age, relative prevalence and treatment profile in JIA subtypes at the beginning of the transitional care. Methods Descriptive and cross-sectional study of patients with JIA (according to ILAR criteria), diagnosed and treated in the pediatric rheumatology service and seen in the transitional care unit of the adult rheumatology service within the same tertiary hospital between January 2013 and December 2018. Demographic, clinical, analytical and treatment data were collected at the first visit to the transitional care unit. Results 72 patients were included (46 women) mean age at diagnosis of 9.5 ± 4.6y and mean of 11.3 ± 4.36y from diagnosis to the first visit at the transitional care unit. 27.7% were diagnosed with oligoarticular JIA, 20.8% with arthritis-enthesitis JIA, 19.4% with Rheumatoid Factor negative (RF-) polyarticular JIA, 11.1% with systemic JIA, x9.7% with undifferentiated JIA, 5.5% with Rheumatoid Factor positive (RF+) polyarticular JIA and 5.5% of psoriatic arthritis. The mean age at the first visit to the transitional care unit was 20.81 ± 2.96y (no differences between subtypes). Oral ulcers (20.8%), anterior uveitis (13.8%) and enthesitis (13.8%) were the most frequent extra-articular manifestations. 56.9% had antinuclear antibodies (ANA) titers 〉 1/160 at some point in course of disease (Table 1). 43% were treated with methotrexate, 38% with biological therapies, 11.% with glucocorticoids (GC) and 22.% had no treatment. Table 1. JIA subtypes Gender Age at diagnosis Age at first visit transicion care unit ANA positivity TNF alfa inhibitors Tocilizumab Abatacept Methotrexate Leflunomide GC NSADs No treatment n (%) (% woman ) Mean (SD ) Mean (SD ) Oligoarticular (n=20) 77% 7,35 (4,88) 20,55 (2,91) 85% Etanercept: 3 (15%) 1 (5%) 0 11 (55%) 1 (5%) 3 (15%) 5 (25%) 5 (25%) Adalimumab: 2 (10%) Arthritis/ Enthesitis 27% 10,07 (4,3) 19,67 (2,38) 33,33% Etanercept: 4 (26,66%) 0 0 6 (40%) 1 (6,67%) 0 5 (33.33%) 2 (13,33%) Adalimumab: 1 (6,66%) (n=15) RF- Polyarticular (n=14) 77% 10,64 (4,99) 22,14 (2,48) 57,14% Etanercept: 2 (14,28%) 1 (7,14%) 0 7 (50%) 0 1 (7,14%) 7 (50%) 2 (14,28%) Adalimumab: 2 (14,28%) Infliximab: 1 (7,14%) Systemic (n=8) 56% 9,12 (4,88) 20,75 (3,58) 12,5% Etanercept: 1 (12,5%) 1 (12,5%) 0 2 (25%) 0 2 (25%) 0 3 (37,5%) Adalimumab: 1 (12,5%) Infliximab: 1 (12,5%) Undifferenciated (n=7) 61% 11 (2,24) 19,57 (3,46) 57,14% Etanercept: 1 (14,29%) 0 0 1 (14,29%) 0 1 (14,29%) 2 (28,57%) 3 (20%) RF+ Polyarticular (n=4) 100% 14,5 (1,29) 22,5 (4,04) 75% 0 1 (25%) 1 (25%) 3 (75%) 0 0 2 (50%) 1 (25%) Psoriatic Arthritis (n=4) 50% 7,5 (σ: 3,7) 22,25 (σ: 2,2) 75% Etanercept: 1 (25%) 2 (50%) 0 1 (25%) 0 0 0 0 Golimumab: 1 (25%) Conclusion The oligoarticular form was the most prevalent subtype of JIA, similar to previously published series from Western Europe. The first visit at the transition care unit occurred significantly later than recommended by various authors. The most frequent treatment was methotrexate. The use of biological therapies was high, with TNF alpha inhibitors being the most widely used, especially etanercept. The use of glucocorticoids was low. A non-negligible number of patients were treatment free. Disclosure of Interests None declared
Type of Medium:
Online Resource
ISSN:
0003-4967
,
1468-2060
DOI:
10.1136/annrheumdis-2022-eular.4126
Language:
English
Publisher:
BMJ
Publication Date:
2022
detail.hit.zdb_id:
1481557-6
Permalink
